KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inovio Pharmaceuticals (INO) Interest Expenses (2019 - 2024)

Inovio Pharmaceuticals (INO) has disclosed Interest Expenses for 6 consecutive years, with $177833.0 as the latest value for Q1 2024.

  • Quarterly Interest Expenses fell 43.27% to $177833.0 in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $177833.0 through Dec 2024, down 85.46% year-over-year, with the annual reading at $177833.0 for FY2024, 85.46% down from the prior year.
  • Interest Expenses hit $177833.0 in Q1 2024 for Inovio Pharmaceuticals, down from $282325.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $2.8 million in Q2 2020 to a low of $177833.0 in Q1 2024.
  • Historically, Interest Expenses has averaged $781968.9 across 5 years, with a median of $313488.0 in 2022.
  • Biggest five-year swings in Interest Expenses: skyrocketed 327.24% in 2020 and later tumbled 83.6% in 2021.
  • Year by year, Interest Expenses stood at $1.1 million in 2020, then tumbled by 55.03% to $480313.0 in 2021, then plummeted by 34.73% to $313488.0 in 2022, then fell by 9.94% to $282325.0 in 2023, then crashed by 37.01% to $177833.0 in 2024.
  • Business Quant data shows Interest Expenses for INO at $177833.0 in Q1 2024, $282325.0 in Q4 2023, and $313488.0 in Q3 2023.